First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|Advanced Breast Cancer|Triple Negative Breast Cancer
Interventions: DRUG: Atezolizumab|DRUG: Paclitaxel|DRUG: Bevacizumab
Sponsor: MedSIR
Collaborators: Hoffmann-La Roche